About
Contact
Subscribe
e-Edition

Make Home Page

Dashboard
Logout

- My Account
- Dashboard
- Profile
- Saved items
- Logout

Facebook
Twitter

- Site search

Home
News
Sports
- Local Sports
- National Sports
Business
Opinion
A & E
Life
Features & Magazines
Classifieds
Weather
Obituaries
Parcel Pickup

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ucb Sa Unsp/Adr (OP:UCBJY)

156.65 -0.53 (-0.34%)

Streaming Delayed Price Updated: 9:40 AM EST, Feb 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ucb Sa Unsp/Adr

RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program ↗

August 06, 2025

Eli Lilly and Amgen are suing HHS over 340B certifications, claiming ineligible clinics cost them millions in lost revenue.

Via Benzinga

Topics Lawsuit

Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results ↗

June 12, 2025

UCB and Biogen's lupus candidate showed strong Phase 3 results, including fatigue improvement and higher remission versus standard care.

Via Benzinga

Protagonist/Johnson & Johnson Partnered Drug Shows Significant Skin Clearance In Pivotal Psoriasis Study ↗

May 09, 2025

Protagonist and J&J report strong Phase 3 psoriasis data for icotrokinra and unveil potent next-gen IL-17 blocker PN-881 at SID meeting.

Via Benzinga

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline ↗

April 09, 2025

Trump hints at major tariffs on foreign pharmaceuticals, sparking concerns for Indian suppliers and potential hikes in U.S. drug costs.

Via Benzinga

Topics Government Supply Chain World Trade

UCB's Rare Childhood Epilepsy Drug Scores FDA Approval ↗

March 28, 2022

Via Benzinga

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

Europe-Based UCB's Bimzelx Data Reveals Sustained Skin Clearance In Inflammatory Skin Disorders ↗

March 07, 2025

UCB's Bimzelx shows sustained efficacy in psoriasis and hidradenitis suppurativa, with high skin clearance rates and improved symptoms over long-term trials.

Via Benzinga

Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside ↗

November 20, 2024

UCB and Biogen's Phase 3 lupus drug trial shows improved disease activity outcomes, with promising data leading to a second pivotal trial in 2024.

Via Benzinga

FDA Approves UCB's Psoriasis Drug For Expanded Use In Painful Inflammatory Skin Disease ↗

November 20, 2024

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

Via Benzinga

Biogen/UCB Partnered Autoimmune Disease Candidate Hits Primary Goal In Late-Stage Study, Sets Stage Another Pivotal Trial ↗

September 24, 2024

UCB and Biogen announced positive Phase 3 results for dapirolizumab pegol in treating moderate-to-severe systemic lupus erythematosus, showing significant improvement in disease activity after 48...

Via Benzinga

Longboard Pharmaceuticals Boasts High-Value Epilepsy Assets, Analyst Initiates Coverage ↗

September 10, 2024

Truist Securities initiated coverage on Longboard Pharmaceuticals, citing it as a CNS-focused biotech with high-value epilepsy assets.

Via Benzinga

Week In Review: UCB Sells China Drug Portfolio To CBC For $680 Million ↗

August 31, 2024

UCB announced plans to divest its current China five-drug portfolio, narrowing its China focus to commercialize soon-to-arrive late-stage clinical assets. It will sell this “mature” neurology and...

Via Talk Markets

Johnson & Johnson Seeks FDA Approval For Muscle Weakness Drug And Gears Up Showdown With Argenx and UCB ↗

August 29, 2024

Johnson & Johnson has submitted a Biologics License Application (BLA) to the FDA for nipocalimab, seeking its first global approval for generalized myasthenia gravis (gMG). This submission follows...

Via Benzinga

Belgium-Based Pharma Firm UCB To Offload China Neurology, Allergy Business For $680M To Asset Management Companies ↗

August 26, 2024

UCB announces a $680 million strategic divestment deal in China, selling its neurology and allergy business to CBC Group and Mubadala while focusing on innovative therapies in the region.

Via Benzinga

There's Optimism Around Longboard Pharmaceuticals' Anti-Seizure Candidate: Analyst Boosts Price Target ↗

January 02, 2024

Tuesday, Longboard Pharmaceuticals Inc (NASDAQ: LBPH) released topline data from the PACIFIC Phase 1b/2a study evaluating bexicaserin (LP352) for seizures associated with a broad range of...

Via Benzinga

Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst ↗

September 28, 2023

Raymond James initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), a recent reverse merger with the old Magenta Therapeutics.

Via Benzinga

Skin Disease Focused MoonLake Immunotherapeutics Poised To Outshine Rivals, Analyst Asserts ↗

August 31, 2023

Needham initiated coverage on MoonLake Immunotherapeutics (NASDAQ: MLTX) with a Buy rating and

Via Benzinga

FDA Approves Rystiggo: The Only Treatment for Two Most Common Subtypes of Generalized Myasthenia Gravis in Adults ↗

June 27, 2023

The FDA approved UCB SA's (OTC: UCBJF) (OTC: UCBJY) Rystiggo (rozanolixizumab-noli) for generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) or...

Via Benzinga

Cantor On MoonLake Immunotherapeutics - Initiates On Inexpensive Valuation, Strong Catalyst Path ↗

February 14, 2023

Via Benzinga

The Week Ahead In Biotech (May 30-June 4): FDA Decision For Eton's Partnered Epilepsy Drug, ASCO Conference Gets Underway And More ↗

May 30, 2022

Biotech stocks advanced in the week ended May 27, tracking the overall positive sentiment of the broader market. Notwithstanding the week's strength, the sector has been one of the worst performers for...

Via Benzinga

Biogen-Xbrane Enter License Agreement For Cimzia Referenced Biosimilar, Xcimzane ↗

February 08, 2022

Biogen Inc (NASDAQ: BIIB) and Xbrane Biopharma AB have

Via Benzinga

The Week Ahead In Biotech (Jan. 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, & More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that...

Via Talk Markets

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More ↗

January 23, 2022

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the...

Via Benzinga

UCB's Bispecific Marks Phase 3 Win For Second Psoriatic Arthritis Study ↗

January 21, 2022

UCB SA (OTC: UCBJF) posted topline results from the Phase 3 BE COMPLETE study evaluating Bimzelx (bimekizumab) for active psoriatic arthritis patients who were...

Via Benzinga

ZGNX Stock: The $1.9B UCB Deal That Has Zogenix Shares Zooming Higher Today ↗

January 19, 2022

Zogenix (ZGNX) stock is skyrocketing on Wednesday following news that UCB (UCBJY) intends to acquire the company in a $1.9 billion deal.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For September 2, 2021 ↗

September 02, 2021

Upgrades For Okta Inc (NASDAQ:

Via Benzinga

UCB Gets EU Approval For Bimekizumab In Psoriasis ↗

August 25, 2021

The European Commission has cleared UCB's (OTC: UCBJF) Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults. UCB's confidence lies in...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 23, 2021 ↗

August 23, 2021

Upgrades JP Morgan upgraded the previous rating for Pearson PLC (NYSE:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 23, 2021 ↗

July 23, 2021

Upgrades Craig-Hallum upgraded the previous rating for Lindblad Expeditions Holdings Inc (NAS...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 9, 2021 ↗

July 09, 2021

h2>Upgrades According to HSBC, the prior rating for NIO Inc (NYSE:

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Sections

News
Sports
Opinion
Photo Galleries
Videos
Local Events
Classifieds
Obituaries

Services

About
Contact
Personnel
Advertise
Subscription Services
Promote Your Event
Dealer Locations
Email Alerts
Submission Forms

Contact Information

chroniclejournal.com
75 S. Cumberland Street
Thunder Bay, ON P7B 1A3
Phone: 807 343 6200
Email: circulation@chroniclejournal.com

Facebook
Twitter

Browser Compatibility

Your browser is out of date and potentially vulnerable to security risks.
We recommend switching to one of the following browsers:

Microsoft Edge Google Chrome Firefox

Ucb Sa Unsp/Adr (OP:UCBJY)

All News about Ucb Sa Unsp/Adr

Sections

Services

Contact Information

Follow Us